Poteligeo and Livtencity may likely be reimbursed in April

drug pricing negotiations for the two drugs are complete

Pricing negotiations with the National Health Insurance Service have been ongoing after passing the Drug Reimbursement Evaluation Committee meeting in December last year

Interest rises on whether Enhertu Inj and morning sickness drugs will also be reimbursed before the general elections

Two rare disease drugs, Poteligeo (mogamulizumab, Kyowa Kirin Korea) and Livtencity (maribavir, Takeda Pharmaceuticals Korea), are likely to be added to the reimbursement list next month after completing pricing negotiations with the National Health Insurance Service.

 

According to industry sources on the 13th, the companies have completed pricing negotiations with the NHIS for the two drugs.

 

Accordingly, the drugs will likely be reimbursed from April if the negotiation results are reported to the Health Insurance Policy Deliberation Committee at the end of this month.

 

The two drugs are both rare disease drugs that have passed the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee review in December last year.

 

Poteligeo Inj is a treatment for patients with mycosis fungoides (MF) or Sézary syndrome (SS).

 

MF and SS are two typical types of cutaneous T-cell lymphoma (CTCL), a chronic condition that causes disfiguring lesions, itching, and psychological stress that affects the patient’s quality of life.

 

Poteligeo is a a humanized monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4), which is frequently expressed on leukemic cells of certain hematologic malignancies including CTCL, such as MF and SS.

 

Livtencity is an antiviral drug used to treat post-transplant cytomegalovirus (CMV) infection.

 

is a virus that remains asymptomatic and latent after infection, but reactivates when the immune system is compromised, such as after organ transplantation, causing serious disease.

 

Livtencity is an oral antiviral agent that inhibits viral proliferation by reducing the activity of the UL97 protein kinase,’ which is involved in the replication and proliferation of the cytomegalovirus.

 

Kyowa Kirin accepted the negotiated price at the DREC level and negotiated only the estimated reimbursement amount with the NHIS for Poteligeo.

 

In addition, whether ‘Enthertu 100mg Inj (trastuzumab deruxtecan),’ a targeted therapy for breast 100 mg (trastuzumab deruxtecan, Daiichi Sankyo, Korea) and 7 morning sickness drugs (doxylamine succinate -pyridoxine hydrochloride) will also be listed for reimbursement in April is receiving attention.

 

Currently, Enhertu, which patient groups have been requesting coverage, was dramatically approved in February after struggling through the pharmacoeconomic evaluation process.

 

The government plans to expedite the drug's reimbursement due to the high demand from society.

 

Negotiations are currently underway with the MFDS on its reimbursed price and is likely to be approved in April.

 

The coverage of morning sickness drugs is being promoted as a government measure to support pregnant women with the promise of exceptional treatment.

 

Although negotiations are yet to begin, the process is expected to progress rapidly.